时间：2026-09-24 04:00:25 来源：Urban Hub

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Hopeful Breakthrough Pill Tested in Both Forms of Common Inherited Heart Disease**

*Phase‑2 data on EDG‑7500 were presented in Munich, covering both forms of hypertrophic cardiomyopathy. The drug remains investigational and unapproved.*

---

### Introduction

At the 2024 European Cardiology Congress in Munich, biotech firm **EvoGenix Therapeutics** unveiled interim results from a Phase‑2 trial of its novel oral agent **EDG‑7500**. The compound was evaluated in patients with the two most prevalent genetic variants of **hypertrophic cardiomyopathy (HCM)**—the obstructive (oHCM) and non‑obstructive (nHCM) phenotypes. With an estimated 1 in 500 people worldwide carrying the mutation, HCM remains a leading cause of sudden cardiac death in young adults. The presentation marks the first time a single molecule has been tested across both disease subtypes in a controlled setting.

### Key Developments

- **Efficacy signals**: In the 120‑patient cohort, EDG‑7500 produced a mean reduction of 8 mm Hg in left‑ventricular outflow tract gradient for oHCM participants and a 12 % improvement in peak oxygen uptake (VO₂ max) for nHCM subjects.
- **Safety profile**: Adverse events were limited to mild gastrointestinal upset in 9 % of participants; no serious cardiac arrhythmias were reported.
- **Biomarker response**: Serum levels of N‑terminal pro‑BNP fell by an average of 22 % across the trial, indicating a favorable effect on cardiac stress.

EvoGenix’s Chief Medical Officer, Dr. Lena Kraus, emphasized that “the dual‑phenotype design of this study reflects real‑world practice, where clinicians must manage both obstructive and non‑obstructive HCM with a single therapeutic strategy.”

### Industry Analysis

The HCM market, valued at roughly **$2.3 billion** in 2023, is dominated by surgical septal myectomy, alcohol septal ablation, and a handful of FDA‑approved myosin inhibitors such as mavacamten. However, existing drugs are limited by dosing complexities, drug‑drug interactions, and high cost. EDG‑7500’s oral formulation and apparent tolerability could disrupt this landscape, especially if Phase‑3 trials confirm the early efficacy signals.

Analysts at **MediBridge Research** note that “a pill that

上一篇：Snag adidas Amplifier 28L Laptop Backpack for Just $32 with Prime Shipping
下一篇：Shocking Moment: Overweight Knicks Fan Caught Littering in Trash Can Heist

• ·Elanco Animal Health's Financial Future Revealed in Latest SEC 10-K Report Details
• ·Gap's stumble sparks daring shake‑up: Marketing veteran named Old Navy CEO
• ·Keffe D Convicted for Tupac Shakur Murder, Fans React with Shock
• ·Today's Top Cybersecurity Breakthroughs: Must-Read Hacker News for August 31, 2026
• ·Trump Unleashes Fierce Attack on Big Oil, Shaking Global Markets
• ·UCLA Shocks Fans: Fires AD Jarmond, Appoints Former Lakers Exec
• ·Administrative Overload Is Stunting Your Firm’s Growth, 8am Reveals Why
• ·Tragic Himalayan Disaster Leaves 80 Americans Missing as 903 Die
• ·True North Targets Massive Copper Bonanza in Cloncurry, Queensland Mining Revival
• ·Venezuela's 100-Year Oil Deal Sparks U.S.-Backed Controversy Over 17 Fields
• ·Fans Thrilled as Shraddha Kapoor, Preity Zinta, Sonu Sood Spot Downtown
• ·Australian Moto Star Shines from Ironman to Warsaw, Idaho, Wodonga
• ·Unsettling San Francisco Ruins and Obsessive Drama Unfold in White Sky #4
• ·Lionel Richie Hospitalized After Shocking Muny Concert Collapse
• ·RXT Investors Set to Lead High‑Stakes Rackspace Fraud Lawsuit
• ·Lance Leipold Reveals Emotional Reason Behind Naming Isaiah Marshall Kansas' Starting QB